The LUVEN screening test method created by scientist of our company detects cancer at its early stages with the accuracy of up to 96% only comparable to biopsy. None of the existing diagnostic techniques has such a high diagnostic accuracy.
The LUVEN technology allows to diagnose the disease at its early stages, thus, giving a chance to thousands of people to prevent its further development.
For more than 20 years the Ukrainian scientists have been developing a diagnostic method based on cyto-morphological and cyto-biophysical properties of the buccal epithelial cells. In 2004 at Fenix Cancer Research Center, they continued their research and, finally, came up and implemented an experimental method. A new method of biomaterial analysis allowed to establish a cancer diagnosis at its early stages and to assess predisposition to cancer. A great success in this medical field opened a door to new possibilities,including cancer prevention and therapy. The longstanding scientific research in this field culminated in development of The Luven diagnostic system.
Why is it critical to detect cancer in its early stage?
Around 10 mln people worldwide are annually diagnosed with cancer, with every third patient dying from it. One of the main reasons of such a high mortality rate is late diagnosis.
According to statistics:
This is why one should get a check-up as often as possible, thus preventing the disease progression.
Regardless of the rapid development of modern medicine and biology cancer, annually, takes millions of human lives. One cancer patient, worldwide, dies from this disease every 30 seconds.
The key to successful cancer treatment is early diagnosis.
Our History
The development of this method started in early 1983 at the research institute, chair for genetics. Based on the cellular theory by Rudolf Vichow, a team of scientists was working on a diagnostic method and studying buccal cells. Ms. Galina Shchukina, a genetic scientist and cytologist, was at the head of the scientific research. She conducted an in-depth study of scientific papers describing a new biophysical concept of the gene activity regulation based on the role of relationship between homologous chromosomes and genome. Together with Mr. Alexander Shchukin, a nuclear physicist, they invented an ion trap allowing to estimate bioelectric charge of cells. Further research and studies of this concept laid the basis for a new diagnostic method born in 2004, according to which any changes in the human body reflect on cells, including buccal epithelial cells. It was the first milestone in the development of LUVEN a unique diagnostic and treatment system. As of today, this method allowed to collect statistical data on tests of more than twenty thousand of patients.
Why is it lucrative?
Cancer research is an acute social problem, in view of this they cast a veil on profits of medical companies. However, in-vitro diagnostics, and particularly cancer diagnostics, is a huge and most rapidly developing sector, with the potential global market of DNA cancer tests worth about $20 bn.
Unlike the majority of projects involving ICO, our company has already completed 90% of the whole thing. The presale period starts on November 15 until December 6, 2017. The token sale is planned from January 15 to February 28, 2018.
I possessori di token hanno due opportunità:
Token standard Ethereum ERC20.
1983
2004
2010
2014
2015
2016 - 2017
Settembre - ottobre 2017
Gennaio 2018
2018
2019
2020
2021
verificata 0%
Attenzione. C'è il rischio che i membri non verificati non siano effettivamente membri del team
Questa offerta si basa su informazioni fornite esclusivamente dall'offerente e altre informazioni disponibili pubblicamente. L'evento di vendita o scambio di token non è interamente correlato a ICOholder e ICOholder non ha alcun coinvolgimento in esso (inclusi eventuali supporti tecnici o promozioni). Le vendite di token elencate da persone con cui ICOholder non ha relazioni sono mostrate solo per aiutare i clienti a tenere traccia dell'attività che si svolge all'interno del settore generale dei token. Questa informazione non è intesa come un consiglio su cui dovresti fare affidamento. È necessario ottenere una consulenza professionale o specialistica o eseguire la propria due diligence prima di intraprendere o astenersi da qualsiasi azione sulla base del contenuto del nostro sito. I termini e le condizioni stipulati dai contributori in relazione all'acquisizione di token sono tra loro e l'emittente del token e ICOholder non è il venditore di tali token. ICOholder non ha alcuna responsabilità legale per qualsiasi dichiarazione fatta da terzi in relazione a qualsiasi vendita di token e qualsiasi richiesta di violazione del contratto deve essere fatta anche direttamente contro l'entità emittente dei token qui elencata.
In caso di dubbi sulla natura, sulla proprietà o sulla legalità di questa vendita di token o delle persone coinvolte, contattare info@icoholder.com con informazioni dettagliate sulle tue preoccupazioni.